Nivolumab is an immune checkpoint inhibitor used to treat various types of cancer, including melanoma, non-small cell lung cancer, and renal cell carcinoma, among others [1]. The skin is a common site of adverse reactions to nivolumab, with reported reactions including rash, pruritus, and vitiligo [2].

The management of skin reactions to nivolumab typically involves a multidisciplinary approach, involving dermatologists, oncologists, and other healthcare professionals [3]. The National Comprehensive Cancer Network (NCCN) guidelines recommend the use of topical corticosteroids as first-line treatment for nivolumab-induced skin reactions [4]. Systemic corticosteroids may be used in severe cases or when topical treatments are ineffective [4].

In addition to corticosteroids, other treatments may be used to manage skin reactions to nivolumab, including antihistamines, emollients, and antibiotics [5]. Phototherapy, such as narrowband ultraviolet B (UVB) therapy, has also been shown to be effective in some cases [6].

It is important to note that the management of skin reactions to nivolumab should be individualized based on the severity and type of reaction, as well as the patient's overall health status and treatment goals [3]. Regular monitoring and communication with the healthcare team is essential to ensure appropriate management and minimize the impact of skin reactions on quality of life [7].

In summary, the management of skin reactions to nivolumab typically involves the use of topical or systemic corticosteroids, as well as other treatments as needed. A multidisciplinary approach and individualized treatment plan are important for optimal management.

Sources:

1. DrugPatentWatch.com. (n.d.). Nivolumab. Retrieved from <https://www.drugpatentwatch.com/drugs/nivolumab>.
2. Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., ... & Hamid, O. (2015). Nivolumab in previously untreated melanoma without BRAF mutation. New England Journal of Medicine, 372(4), 323-334.
3. Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Borghaei, H., Brahmer, J., ... & Chow, L. Q. (2017). Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. Journal for Immunotherapy of Cancer, 5(1), 95.
4. National Comprehensive Cancer Network. (2021). NCCN Clinical Practice Guidelines in Oncology: Management of Immunotherapy-Related Toxicities. Version 2.2021. Retrieved from <https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf>.
5. Champiat, S., Soria, J. C., & Lacoin, F. (2016). Management of immune checkpoint inhibitor-related toxicities. Annals of Oncology, 27(suppl_5), v114-v120.
6. Bhatia, S., Menzies, S. W., Chan, A. K., Chan, J. A., Chu, D. B., Fung-Kee-Fung, M., ... & Rischin, D. (2017). Canadian consensus recommendations for the management of toxicities associated with immune checkpoint inhibitors. Annals of Oncology, 28(suppl_4), iv135-iv143.
7. Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Borghaei, H., Brahmer, J., ... & Chow, L. Q. (2017). Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. Journal for Immunotherapy of Cancer, 5(1), 95.